In September 2018, the Drug Enforcement Agency (“DEA”) placed Epidiolex—a CBD-based drug used to treat severe forms of epilepsy—in Schedule V of the Controlled Substances Act (“CSA”), the lowest classification under the CSA.  That re-scheduling, however, was limited in scope: only drugs approved by the Food and Drug Administration (“FDA”) and containing no more than…